Has Cochlear turned a Corner?

Cochlear as flagged that its profit for this financial year should be towards the lower end of guidance as the rollout of an implant took longer than expected.

For FY26, underlying net profit is expected at the lower end of guidance, currently in the 435 to $460 million range.

In the first half of the financial year, Cochlear has reported a sales revenue growth of 1%, but down 2% in constant currency.

Underlying net profit was down 9% to $195 million.

Cochlear expects a stronger second half... saying product registration and the price setting process for its Nucleus Nexa System are now complete.

And the ear-implant developer will now distribute an interim dividend of $2.15 per share, a similar level to the previous corresponding period.